Matrifen Transdermal patch - Summary of Product Characteristics (SPC)Posology. Matrifen doses should be individualised based upon the status of the patient and should be assessed at regular intervals after application. The lowest effective dose should be used. The patches are designed to deliver approximately 1. Initial dosage selection The appropriate initiating dose of Matrifen should be based on the patient's current opioid use. It is recommended that Matrifen be used in patients who have demonstrated opioid tolerance.

Other factors to be considered are the current general condition and medical status of the patient, including body size, age, and extent of debilitation as well as degree of opioid tolerance. Adults: Opioid- tolerant patients.

The table has been derived from the data sheet, and simplified to match available preparations. When converting, because the patches cover a range of equivalent. We have detected that your browser does not have cookies enabled, which are required to access this site. Please set your browser to accept cookies and then reload. Durogesic DTrans 12 micrograms/hour Transdermal Patch - Summary of Product Characteristics (SPC) by Janssen-Cilag Ltd.

Matrifen 12 micrograms/hour: Each transdermal patch contains 1.38 mg fentanyl in a patch of 4.2 cm 2 and releases fentanyl 12 micrograms/hour. Matrifen 25 micrograms. An equianalgesic (or opioid) chart is a conversion chart that lists equivalent doses of analgesics (drugs used to relieve pain). Equianalgesic charts are used for.

To convert opioid- tolerant patients from oral or parenteral opioids to Matrifen refer to Equianalgesic potency conversion below. The dosage may subsequently be titrated upwards or downwards, if required, in increments of either 1. Matrifen depending on response and supplementary analgesic requirements. Opioid- naive patients. Generally, the transdermal route is not recommended in opioid- na. Alternative routes of administration (oral, parenteral) should be considered. To prevent overdose it is recommended that opioid- na.

Patients can then switch to Matrifen. In the circumstance in which commencing with oral opioids is not considered possible and Matrifen is considered to be the only appropriate treatment option for opioid- na. In such circumstances, the patient must be closely monitored. The potential for serious or life- threatening hypoventilation exists even if the lowest dose of Matrifen is used in initiating therapy in opioid- na. To calculate the appropriate starting dose of Matrifen, follow the steps below. Calculate the 2. 4- hour dose (mg/day) of the opioid currently being used.

Convert this amount to the equianalgesic 2. Table 1 for the appropriate route of administration. To derive the Matrifen dosage corresponding to the calculated 2.

Table 2 or 3 as follows: a. Table 2 is for adult patients who have a need for opioid rotation or who are less clinically stable (conversion ratio of oral morphine to transdermal fentanyl approximately equal to 1. Table 3 is for adult patients who are on a stable, and well- tolerated, opioid regimen (conversion ratio of oral morphine to transdermal fentanyl approximately equal to 1. Table 1: Conversion Table - Multiplication Factors for Converting the Daily Dose of Prior Opioids to the Equianalgesic 2.

Opioid Calculator Conversion Data and Methods. The data upon which the conversions are based are summarized in the table below. All conversions (except methadone) are.

Oral Morphine Dose (mg/day Prior Opioid x Factor = Equianalgesic 2. Oral Morphine Dose)Prior Opioid. Route of Administration. Multiplication Factor.

Morphine oral. 1a parenteral. Buprenorphine sublingual.

Codeine oral. 0. 1. Diamorphine oral. Fentanyl oral- parenteral. Hydromorphone oral.

Ketobemidone oral. Levorphanol oral. Methadone oral. 1. Oxycodone oral. 1. Oxymorphone rectal. Pethidine oral- parenteral. Tapentadol oral. 0.

Tramadol oral. 0. The oral/IM potency for morphine is based on clinical experience in patients with chronic pain. Based on single- dose studies in which an IM dose of each active substance listed was compared with morphine to establish the relative potency. Oral doses are those recommended when changing from a parenteral to an oral route.

Table 2: Recommended starting dosage of Matrifen based upon daily oral morphine dose (for patients who have a need for opioid rotation or for clinically less stable patients: conversion ratio of oral morphine to transdermal fentanyl is approximately equal to 1. Oral 2. 4- hour morphine(mg/day)Matrifen. Dosage(mcg/h)< 9. In clinical studies these ranges of daily oral morphine doses were used as a basis for conversion to Matrifen. Table 3: Recommended starting dosage of Matrifen based upon daily oral morphine dosage (for patients on stable and well tolerated opioid therapy: conversion ratio of oral morphine to transdermal fentanyl is approximately equal to 1.

Oral 2. 4- hour morphine(mg/day)Matrifen Dosage(mcg/h)< 4. Initial evaluation of the maximum analgesic effect of Matrifen cannot be made before the patch is worn for 2. This delay is due to the gradual increase in serum fentanyl concentration in the 2. Previous analgesic therapy should therefore be gradually phased out after the initial dose application until analgesic efficacy with Matrifen is attained.

Dose titration and maintenance therapy. The Matrifen patch should be replaced every 7. The dose should be titrated individually on the basis of average daily use of supplemental analgesics, until a balance between analgesic efficacy and tolerability is attained. Download Ilok Crack For Pro Tools 9 Ilok. Dosage titration should normally be performed in 1. After an increase in dose, it may take up to 6 days for the patient to reach equilibrium on the new dose level.

Therefore after a dose increase, patients should wear the higher dose patch through two 7. More than one Matrifen patch may be used for doses greater than 1. Patients may require periodic supplemental doses of a short- acting analgesic for “breakthrough” pain. Some patients may require additional or alternative methods of opioid administration when the Matrifen dose exceeds 3. If analgesia is insufficient during the first application only, the Matrifen patch may be replaced after 4. If the patch needs to be replaced (e.

This may result in increased serum concentrations (see section 5. Discontinuation of Matrifen.

If discontinuation of Matrifen is necessary, replacement with other opioids should be gradual, starting at a low dose and increasing slowly. This is because fentanyl levels fall gradually after Matrifen is removed.

It may take 2. 0 hours or more for the fentanyl serum concentrations to decrease 5. In general, the discontinuation of opioid analgesia should be gradual in order to prevent withdrawal symptoms (see section 4. Opioid withdrawal symptoms are possible in some patients after conversion or dose adjustment.

Tables 1, 2, and 3 should only be used to convert from other opioids to Matrifen and not from Matrifen to other therapies to avoid overestimating the new analgesic dose and potentially causing overdose. Special populations Elderly patients Elderly patients should be observed carefully and the dose should be individualised based upon the status of the patient (see section 4.

In opioid- na. In these cases, only Matrifen 1. Renal and hepatic impairment Patients with renal or hepatic impairment should be observed carefully and the dose should be individualised based upon the status of the patient (see section 4. In opioid- na. In these cases, only Matrifen 1. Paediatric population.

Children aged 1. 6 years and above. Follow adult dosage.

Children aged 2 to 1. Matrifen should be administered only to those opioid- tolerant paediatric patients (ages 2 to 1. To convert paediatric patients from oral or parenteral opioids to Matrifen, refer to Equianalgesic potency conversion (Table 1), and Recommended Matrifen dosage based upon daily oral morphine dose (Table 4). Coast To Coast Am Hacking Games. Table 4: Recommended Matrifen dosage for paediatric patients.

Oral 2. 4- hour morphine(mg/day)Matrifen Dosage(mcg/h)3. Conversion to Matrifen dosages greater than 2. Table 2). 2 In clinical studies these ranges of daily oral morphine doses were used as a basis for conversion to Matrifen. In two paediatric studies, the required fentanyl transdermal patch dose was calculated conservatively: 3.

It should be noted that this conversion schedule for children only applies to the switch from oral morphine (or its equivalent) to fentanyl transdermal patches. The conversion schedule should not be used to convert from transdermal fentanyl into other opioids, as overdosing could then occur.

The analgesic effect of the first dose of Matrifen patches will not be optimal within the first 2. Therefore, during the first 1. Matrifen, the patients should be given the previous regular dose of analgesics. In the next 1. 2 hours, these analgesics should be provided based on clinical need.